Alpelisib Patent Expiration
Alpelisib was first introduced by Novartis Pharmaceuticals Corp
Alpelisib Patents
Given below is the list of patents protecting Alpelisib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Vijoice | US11433059 | Byl719 (Alpelisib) For Use In The Treatment Of Pik3Ca-Related Overgrowth Spectrum (Pros-Cloves Syndrome) | Feb 17, 2037 | Novartis |
| Vijoice | US12427141 | Byl719 (Alpelisib) For Use In The Treatment Of Pik3Ca-Related Overgrowth Spectrum (Pros-Cloves Syndrome) | Feb 17, 2037 | Novartis |
| Piqray | US8227462 | Pyrrolidine-1,2-dicarboxamide derivatives | Apr 29, 2033 | Novartis |
| Vijoice | US8227462 | Pyrrolidine-1,2-dicarboxamide derivatives | Apr 29, 2033 | Novartis |
| Piqray | US8476268 | Pyrrolidine-1,2-dicarboxamide derivatives | Sep 10, 2029 | Novartis |
| Vijoice | US8476268 | Pyrrolidine-1,2-dicarboxamide derivatives | Sep 10, 2029 | Novartis |
Alpelisib's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Alpelisib:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
